We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
NEO KUMA Ventures, the UK’s first investment fund dedicated solely to psychedelic healthcare, has today (3rd June) announced its investment in seven innovative healthcare companies.
The largest placebo-controlled psychedelics study to date concluded that the psychological benefits of microdoses of psychedelics are likely due to the placebo effect.
A research center that will assess the use of psychedelic drugs to treat conditions such as addiction, alcoholism, and depression was announced by Johns Hopkins University.